J&J Wants A Piece Of Gilead's HIV Market [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
Summary Johnson & Johnson announced that it had obtained FDA approval for its HIV drug Symtuza (darunavir). Approval for the treatment of patients with HIV comes on the heels of two phase 3 trials where Symtuza was shown to maintain virological suppression in 95% of the patients. It expected that Biktarvy could reach peak sales between $6 to $10 billion, which means Symtuza has the potential to earn a good chunk of that. Symtuza is being used to treat HIV patients who have never received treatment before and for those who are already virologically suppressed on stable antiretroviral regimen. It is estimated that the HIV market could possibly reach $22.5 billion by 2025. Recently, Johnson & Johnson ( JNJ ) announced that it had obtained FDA approval for its antiretroviral drug known as darunavir to treat patients with HIV. This newly approved drug will allow the company to compete against a host of other big pharmaceutical c
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Ethereum price today: ETH is down 0.44% today [USA TODAY]USA TODAY
- James Brodie of Johnson & Johnson MedTech Appointed Chair of the Medtech Canada Board of Directors [Yahoo! Finance]Yahoo! Finance
- Drugmakers in Medicare Price Negotiations Spent Less on Research Than on Shareholder Payments, Marketing and Overhead: Report [Yahoo! Finance]Yahoo! Finance
- Mike Vinokur's Top Picks: May 9, 2024 [BNN Bloomberg (Canada)]BNN Bloomberg
- 3 Top Dividend Stocks to Maximize Your Retirement Income [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/10/24 - Form 13F-HR
- 5/3/24 - Form 4
- 5/1/24 - Form 10-Q
- JNJ's page on the SEC website